| scholarly article | Q13442814 |
| P356 | DOI | 10.3389/FNCEL.2016.00293 |
| P8608 | Fatcat ID | release_c3osxtizgnfo7gfadga64qr53e |
| P932 | PMC publication ID | 5177648 |
| P698 | PubMed publication ID | 28066188 |
| P50 | author | Janina Deusser | Q58777336 |
| Jürgen Winkler | Q67212212 | ||
| P2093 | author name string | Zacharias Kohl | |
| P2860 | cites work | Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction. | Q42872557 |
| Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study | Q42994792 | ||
| A progressive dopaminergic phenotype associated with neurotoxic conversion of α-synuclein in BAC-transgenic rats | Q43247253 | ||
| Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study | Q44324829 | ||
| Positron emission tomography of striatal serotonin transporters in Parkinson disease | Q44585433 | ||
| Dopamine-transporter imaging and visuo-motor testing in essential tremor, practical possibilities for detection of early stage Parkinson's disease. | Q44984892 | ||
| Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms | Q45749080 | ||
| Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease | Q46935041 | ||
| The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson's disease | Q47400257 | ||
| Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease. | Q47822108 | ||
| Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications | Q48088787 | ||
| Noradrenaline, dopamine and serotonin levels and metabolism in the human hypothalamus: observations in Parkinson's disease and normal subjects | Q48157915 | ||
| Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. | Q48587838 | ||
| Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson's disease using disector counts. | Q48616749 | ||
| The neuropathologic basis of different clinical subgroups of Parkinson's disease. | Q48633612 | ||
| Pink1-deficiency in mice impairs gait, olfaction and serotonergic innervation of the olfactory bulb. | Q48698653 | ||
| Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease. | Q49095990 | ||
| α-Synuclein BAC transgenic mice as a model for Parkinson's disease manifested decreased anxiety-like behavior and hyperlocomotion. | Q50583895 | ||
| Monoamines in the human neostriatum: Topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor | Q51116310 | ||
| The number of nerve cells in the substantia nigra in paralysis agitans | Q51245671 | ||
| In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease | Q64786334 | ||
| Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis | Q64865584 | ||
| Age-specific progression of nigrostriatal dysfunction in Parkinson's disease | Q83234559 | ||
| Animal models of Parkinson's disease | Q83260343 | ||
| α-Synuclein induced toxicity in brain stem serotonin neurons mediated by an AAV vector driven by the tryptophan hydroxylase promoter | Q27313863 | ||
| Staging of brain pathology related to sporadic Parkinson's disease | Q28131702 | ||
| Epidemiology of Parkinson's disease | Q29614901 | ||
| Ageing and Parkinson's disease: substantia nigra regional selectivity | Q29615835 | ||
| Animal models of Parkinson's disease: vertebrate genetics | Q30429583 | ||
| Formation of α-synuclein Lewy neurite-like aggregates in axons impedes the transport of distinct endosomes | Q30607522 | ||
| Severely impaired hippocampal neurogenesis associates with an early serotonergic deficit in a BAC α-synuclein transgenic rat model of Parkinson's disease | Q30795299 | ||
| Neuroimaging in Parkinson disease: from research setting to clinical practice | Q30868628 | ||
| The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induces apoptosis in mouse nigrostriatal glia. Relevance to nigral neuronal death and striatal neurochemical changes. | Q33183865 | ||
| Characterisation of behavioural and neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of Parkinson's disease | Q33596638 | ||
| Clinical progression in Parkinson disease and the neurobiology of axons. | Q34052764 | ||
| Functional imaging of non-motor signs in Parkinson's disease. | Q34095416 | ||
| Brain serotonin transporter binding in non-depressed patients with Parkinson's disease | Q34619565 | ||
| Spared caudal brainstem SERT binding in early Parkinson's disease | Q34724279 | ||
| The brainstem pathologies of Parkinson's disease and dementia with Lewy bodies. | Q35427654 | ||
| Axon degeneration in Parkinson's disease | Q35923102 | ||
| Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease | Q36063269 | ||
| Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. | Q36865849 | ||
| Disease duration and the integrity of the nigrostriatal system in Parkinson's disease | Q37043102 | ||
| Serotonergic dysfunction in the A53T alpha-synuclein mouse model of Parkinson's disease | Q37092527 | ||
| Functional imaging in Parkinson disease. | Q37138838 | ||
| Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. | Q37221349 | ||
| Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model | Q37240678 | ||
| Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients | Q37602233 | ||
| Neuropathology of non-motor features of Parkinson disease | Q37677151 | ||
| Serotonin innervation of basal ganglia in monkeys and humans | Q37888035 | ||
| Psychosis, apathy, depression and anxiety in Parkinson's disease | Q37975845 | ||
| Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems | Q38123275 | ||
| Nonmotor features of Parkinson's disease subtypes | Q38727963 | ||
| Microtubule depolymerization potentiates alpha-synuclein oligomerization | Q39692472 | ||
| Fetal striatum- and ventral mesencephalon-derived expanded neurospheres rescue dopaminergic neurons in vitro and the nigro-striatal system in vivo | Q39983332 | ||
| Impairment of microtubule-dependent trafficking by overexpression of alpha-synuclein | Q40199182 | ||
| Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. | Q40273125 | ||
| Parkinson's disease. Second of two parts | Q40840040 | ||
| Non-Motor symptoms in Portuguese Parkinson's Disease patients: correlation and impact on Quality of Life and Activities of Daily Living | Q40971563 | ||
| Dopaminergic neurons differentiating from LRRK2 G2019S induced pluripotent stem cells show early neuritic branching defects | Q41117800 | ||
| Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease | Q41346993 | ||
| Striatal dopamine deficiency in Parkinson's disease: role of aging | Q41993839 | ||
| Biochemical aspects of Parkinson's disease | Q42460123 | ||
| Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. | Q42477740 | ||
| Serotonin innervation of human basal ganglia | Q42484813 | ||
| P921 | main subject | dopamine | Q170304 |
| P304 | page(s) | 293 | |
| P577 | publication date | 2016-12-22 | |
| P1433 | published in | Frontiers in Cellular Neuroscience | Q2131509 |
| P1476 | title | Early Degeneration of Both Dopaminergic and Serotonergic Axons - A Common Mechanism in Parkinson's Disease | |
| P478 | volume | 10 |
| Q48171351 | An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition. |
| Q90263483 | Bioenergetics and Autophagic Imbalance in Patients-Derived Cell Models of Parkinson Disease Supports Systemic Dysfunction in Neurodegeneration |
| Q64102380 | CAV-2 Vector Development and Gene Transfer in the Central and Peripheral Nervous Systems |
| Q47925117 | Culture of Rat Mesencephalic Dopaminergic Neurons and Application to Neurotoxic and Neuroprotective Agents |
| Q89619608 | Experimental Traumatic Brain Injury Induces Chronic Glutamatergic Dysfunction in Amygdala Circuitry Known to Regulate Anxiety-Like Behavior |
| Q39324877 | Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias |
| Q61799594 | Long non-coding RNA repertoire and open chromatin regions constitute midbrain dopaminergic neuron - specific molecular signatures |
| Q52363911 | Mechanisms of α-Synuclein Induced Synaptopathy in Parkinson's Disease. |
| Q40500475 | Neuroprotective potential of Quercetin in combination with piperine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. |
| Q91762178 | New perspectives in iron chelation therapy for the treatment of Parkinson's disease |
| Q39229450 | Non-human primate models of PD to test novel therapies |
| Q90597572 | The PERK-Dependent Molecular Mechanisms as a Novel Therapeutic Target for Neurodegenerative Diseases |
| Q96576824 | The human motor cortex microcircuit: insights for neurodegenerative disease |
Search more.